Randox Laboratories Ltd
Randox Laboratories Ltd
Randox Laboratories Ltd. | Date: 2017-02-08
The present invention provides a method and a solid state device for identifying the presence of urothelial cancer in a patient comprising assigning the subject to a sub-population according to smoking habits, measuring the level of each biomarker of a panel of biomarkers in one or more samples obtained from the subject; and correlating the measured levels of the panel of biomarkers with the likelihood of the subject having urothelial cancer such that the subject can be classified as having urothelial cancer or as being a control.
Randox Laboratories Ltd. | Date: 2017-01-04
Components for enabling immunodection of methoxetamine are described including immunogens, haptens, antibodies and kits.
Randox Laboratories Ltd. | Date: 2017-02-15
The present invention describes methods for screening for cancer in a subject, by measuring the level of dimeric IL-18 in a sample obtained from the subject, and comparing that level with the level in a normal control sample. The present invention also describes an assay for screening for cancer in a subject, by measuring the level of dimeric IL-18 in a sample obtained from the subject, whereby an elevated level of dimeric IL-18 is indicative of cancer.
Randox Laboratories Ltd. | Date: 2017-06-28
An immunoassay method is described which detects O-desmethyltramadol only. This enables an assay of high sensitivity and specificity avoiding false positive results. The unique antibodies incorporated in the immunoassay method can be combined with antibodies which detect mitragynine to provide an assay which increases the possibility of detecting the commonly found drug combination of O-desmethyltramadol and mitragynine.
Randox Laboratories Ltd. | Date: 2017-05-03
A liquid sample collection device is provided. The liquid sample collection device comprises a housing including a liquid collection chamber, and a liquid supply conduit extending from an inlet port and in use generally downwardly to the collection chamber, wherein the collection chamber includes an air vent port located such that in use liquid supplied to the collection chamber through the liquid supply conduit displaces air through the air vent port, and wherein the liquid supply conduit follows a meandering path including at least one air trap section defined at the junction between portions of the conduit extending with upward and downward components respectively, whereby in use once the air vent port is closed, air is displaced along the liquid supply conduit until it is trapped by the air trap section thereby preventing further liquid flow through the conduit.
Randox Laboratories Ltd. | Date: 2017-08-23
According to the invention there is a microfluidic chip (1) that includes at least two layers (10) forming a stack of layers, each layer of which has at least one flow channel (14); a bore (16) extending through the layers and communicating with a plurality of flow channels; and a valve (20), which has a shaft (22) with a recess (222) in a side of the shaft for fluid to flow through. The shaft is rotatably mounted in the bore, and has a first position in which the recess is aligned with each of at least two flow channels of the plurality of flow channels thereby providing a flow path between said at least two flow channels, and a second position in which the recess is unaligned with at least one of said at least two flow channels the flow path between said at least two flow channels thereby being closed. This allows a fluid flow path between two flow channels to be open and closed by rotation of the shaft so that fluid in the microfluidic chip can be redirected to allow the chip to have greater capability and by using a minimal amount of space on the chip to do so.
Randox Laboratories Ltd. | Date: 2017-03-13
The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.
Randox Laboratories Ltd. | Date: 2017-06-14
The invention relates to a novel antibody which binds to C-SLPI selected from the group consisting of SEQ ID NOs: 3 and 4.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: ICT-29-2016 | Award Amount: 15.57M | Year: 2017
PIXAPP will establish the worlds first open access Photonic Integrated Circuit (PIC) assembly & packaging Pilot Line. It combines a highly-interdisciplinary team of Europes leading industrial & research organisations. PIXAPP provides Europes SMEs with a unique one-stop-shop, enabling them to exploit the breakthrough advantages of PIC technologies. PIXAPP bridges the valley of death, providing SMEs with an easy access route to take R&D results from lab to market, giving them a competitive advantage over global competition. Target markets include communications, healthcare & security, which are of great socio-economic importance to Europe. PIXAPPs manufacturing capabilities can support over 120 users per year, across all stages of manufacturing, from prototyping to medium scale manufacture. PIXAPP bridges missing gaps in the value chain, from assembly & packaging, through to equipment optimisation, test and application demonstration. To achieve these ambitious objectives, PIXAPP will; 1) Combine a group of Europes leading industrial & research organisations in an advanced PIC assembly & packaging Pilot Line facility.2) Develop an innovative Pilot Line operational model that coordinates activities between consortium partners & supports easy user access through a single entry point. 3) Establish packaging standards that provide cost-efficient assembly & packaging solutions, enabling transfer to full-scale industrial manufacture. 4) Create the highly-skilled workforce required to manage & operate these industrial manufacturing facilities.5) Develop a business plan to ensure Pilot Line sustainability & a route to industrial manufacturing. PIXAPP will deliver significant impacts to a wide stakeholder group, highlighting how industrial & research sectors can collaborate to address emerging socio-economic challenges.
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2015 | Award Amount: 2.12M | Year: 2016
MAST4HEALTH is set on the concept of a multidisciplinary approach to assess a non-pharmacological intervention for managing NAFLD/NASH, one of the most common complications of obesity and diabetes mellitus in Western populations affecting approximately 50% of diabetics and 76% of obese patients. Because of limitations in current NAFLD treatment therapies, many new efforts focus on exploring non-pharmacologic means for managing the disease and in particular through dietary substances or bioactive phytochemicals in fruits, vegetables, and plants or their products. MAST4HEALTH aims at exploring the effect of Mastiha, a natural product of Greece which was recently shown to possess antioxidant/anti-inflammatory and lipid lowering properties. We designed a multicenter randomized double blind placebo controlled (parallel arm) clinical trial to test the effectiveness of Mastiha supplement as new non-pharmacologic strategy for NAFLD/NASH treatment. MAST4HEALTH will explore gene-diet interactions, more specifically the potential personalized activity of the Mastiha, and correlate genetic and epigenetic markers with metabolomic and intestinal microbiota profiles pre- and post-intervention. The effectiveness of the proposed intervention will be evaluated via clinical and laboratory markers of the disease. To this end, MAST4HEALTH will train a number of researchers and PhD students in multidisciplinary approaches of this survey. MAST4HEALTH is expected to build and enhance cooperation among partners meanwhile strengthening the interaction between our academic and non-academic sectors